NAD+ precursor for long COVID: higher levels are not proven recovery
Study design: Humans; randomized study with 58 participants
The research question
In long COVID, researchers are investigating whether changes in energy metabolism play a role. This study tested nicotinamide riboside, a precursor that the body can use to form NAD+.
What was found?
The randomized study examined, among other things, NAD+ levels and cognitive outcomes. NR increased the NAD+ levels measured, but there were no significant differences between the groups in the primary cognitive outcomes. Thus, the biochemical change was not accompanied by a demonstrable cognitive benefit in this study.
What does this evidence mean?
NR is a different intervention from an NAD+ infusion. The finding does not prove that long COVID can be treated with NAD+ or peptides. In communication, it is essential to distinguish a biomarker change from improvements in concentration, functioning, and other symptoms.
Primary source
Research information, not medical advice. The described study does not establish safe use of an investigational product. Image: AI illustration, not a participant or a photo from the study.
Related research products
View product specifications and available batch documentation. The studies discussed were not conducted with Peptidera products and do not prove the efficacy of our products. For laboratory research only; not for human or animal consumption.